Th17、Th1和Tc1细胞亚群在慢性乙型肝炎及慢加急性重型乙型病毒性肝炎患者中的变化及意义
|
摘要
第一部分Th17、Th1和Tc1细胞亚群在慢性乙型肝炎患者中的变化及意义
慢性乙型肝炎的发病机制十分复杂,宿主免疫调节的紊乱是导致病毒不能有效清除、病情迁延不愈、引起慢性炎症、造成肝脏病变的重要原因。许多研究表明Th1、Th2细胞亚群的比例失衡、功能失调是导致慢性乙肝发病的重要因素。传统上,CD4+辅助T细胞(Th)和CD8+细胞毒性T细胞(Tc)根据各自分泌的细胞因子的不同,可以将T细胞分为两类：Ⅰ类T细胞(Th1和Tc1,合称T1)和Ⅱ类T细胞(Th2和Tc2,合称T2),前者主要分泌干扰素γ(IFN-γ)、白细胞介素(IL)-2、肿瘤坏死因子(TNF)-β,后者主要分泌IL-4、IL-5、IL-6、IL-10和IL-13,并且常以IFN-γ/IL-4代表T1／T2的比例。T1和T2在免疫调节中均发挥重要作用,它们各自分泌的细胞因子对免疫应答效应起关键作用。CD8+T细胞可分为Tc1和Tc2两个细胞亚群,Tc1与Th1亚群相似,可分泌IL-2、IFN-γ等细胞因子并且可发挥细胞毒作用。
Th17细胞是最近发现的一种新的效应性CD4+T细胞亚群,以产生分泌白介素17(IL-17)为特征。Th17细胞与Th1和Th2细胞无论在分化途径、信号转导还是生物学功能等方面均有所不同。大量证据表明Th17细胞通过产生IL-17作用于不同的靶细胞,诱导其他细胞因子产生,参与细胞因子网络调节,触发炎症递质释放,从而介导炎性反应(防御胞外病原菌的感染)、自身免疫性疾病、肿瘤和移植排斥等病理状态的发生和发展。迄今为止,有关慢性乙型肝炎患者外周血中Th17细胞的研究报道很少。
目的
本研究的目的是通过对慢性乙型肝炎患者外周血Th17、Th1和Tc1细胞亚群及血浆细胞因子的检测,进一步探讨三种细胞亚群在慢性乙型肝炎患者发病机制中的作用及评价它们的临床相关性。
方法
应用三色流式细胞术检测慢性乙型肝炎患者和正常对照外周血中Th1、Th17和Tc1细胞占CD3+T细胞的比例。三种细胞亚群的界定分别为：Th17细胞为CD3+CD8-IL-17A+,Th1细胞为CD3+CD8-IFN-γ+,Tc1细胞为CD3+CD8+IFN-γ+；应用ELISA技术检测慢性乙型肝炎患者和正常对照血浆中IL-17和IFN-γ的表达水平。应用逆转录聚合酶链反应(RT-PCR)方法检测IL-17及IFN-γ在慢性乙型肝炎患者和正常对照外周血单个核细胞中的表达。
结果
1、慢性乙型肝炎患者外周血Th1细胞的比例(8.55±1.53％)明显低于正常对照组(10.56±1.91％)(P<0.01),并且慢性乙型肝炎患者Tc1细胞的比例(6.35±1.85％)较正常对照组(9.0±2.79％)亦显著降低(P<0.05)。
2、慢性乙型肝炎患者Th17细胞的比例(1.53±0.52％)较正常对照(0.92±0.20％)显著升高(P<0.05)。
3、在慢性乙型肝炎患者中,Th1与Tc1细胞间存在明显的正相关性(r=0.58,P<0.05),Th17与Thl细胞间亦存在显著的负相关性(r=-0.56,P<0.05),但Th17与Tc1细胞间无相关性。
4、慢性乙型肝炎患者血浆中IFN-γ和IL-17表达水平与正常对照相比均无显著性差异。
5、在慢性乙型肝炎患者中,外周血中Th17细胞亚群的比例与ALT呈明显正相关(r=0.66,P<0.05)。慢性乙型肝炎患者外周血中Th1细胞亚群的比例与ALT呈显著负相关(r=-0.68,P<0.05)。
结论
我们的研究结果进一步表明,在慢性乙型肝炎的异常免疫反应中,Th1和Tc1型免疫反应受到抑制。尤为重要的是,我们研究首次表明,在慢性乙型肝炎发生和发展中,Th17细胞亚群比例增加可能是一个重要的决定因素,调节慢性乙型肝炎患者中Th17细胞的异常可能成为慢性乙型肝炎治疗的新策略。
第二部分Th17、Th1和Tc1细胞亚群在慢加急性重型乙型病毒性肝炎患者中的变化及意义
HBV感染可引起人类急慢性肝炎,与肝硬化和肝细胞癌的发生和发展密切相关,我国是乙型肝炎的高发区,在全球3.5亿HBV携带者中,约9300万,发展为慢性乙型肝炎的患者大约有2500万,其中每年约有1％的乙型肝炎患者发展为重型肝炎。重型肝炎(肝衰竭)可被分为四类：急性肝衰竭(acute liver failure, ALF)、亚急性肝衰竭(subacute liver failure, SALF)、慢加急性肝衰竭(acute-on-chronic liver failure, ACLF)和慢性肝衰竭(chronic liver failure, CLF)、慢加急性肝衰竭是在慢性肝病基础上出现的急性肝脏功能失代偿。
在我们的第一部分实验中,我们已经发现慢性乙型肝炎患者外周血中Th1,Tc1细胞的比例明显低于正常对照。提示患者细胞免疫功能低下,不能有效清除体内的HBV,使HBV持续感染形成慢性化。Th17细胞亚群比例增加可能是一个重要的决定因素。
在我国,慢性乙型病毒性肝炎是引起慢加急性肝衰竭的主要病因,有报道称CHB占ACLF所有病因的80％。由慢性乙型病毒性肝炎所致的慢加急性肝衰竭又称为慢加急性重型乙型病毒性肝炎(ACHBLF)。ACHBLF进展迅速,病情凶险,临床上缺乏特异、有效的治疗手段,绝大部分患者预后较差,易出现各种并发症而危及患者的生命,虽然近年来在ACHBLF的发病机制、临床诊断、治疗等方面取得了很大的进展,但死亡率仍高达50％-60％。目前,慢性乙型肝炎出现急性肝功能失代偿引起ACHBLF精确机制尚不明确,明确其发病机制必将提高ACHBLF的治疗水平,降低其死亡率。
目的
本研究的目的是通过对慢加急性乙型病毒性肝炎患者外周血Th17、Th1和Tc1细胞亚群及血浆细胞因子的检测,进一步探讨三种细胞亚群在慢加急性乙型病毒性肝炎患者发病机制中的作用。
方法
应用三色流式细胞术检测慢加急性乙型病毒性肝炎患者和正常对照外周血中Th1、Th17和Tc1细胞占CD3+T细胞的比例。三种细胞亚群的界定分别为：Th17细胞为CD3+CD8-IL-17A+,Th1细胞为CD3+CD8-IFN-γ+,Tc1细胞为CD3+CD8+IFN-γ+；应用ELISA技术检测慢加急性乙型病毒性肝炎患者和正常对照血浆中IL-17和IFN-γ的表达水平。
结果
1、慢加急性乙型病毒性肝炎患者外周血Th1细胞的比例(8.55±1.53％)明显低于正常对照组(10.56±1.91％)(P<0.01),并且慢加急性乙型病毒性肝炎患者Tc1细胞的比例(6.35±1.85％)较正常对照组(9.0±2.79％)亦显著升高(P<0.05)。
2、慢加急性乙型病毒性肝炎患者Th17细胞的比例(1.53±0.52％)较正常对照(0.92±0.20％)显著升高(P<0.05)。
3、在慢加急性乙型病毒性肝炎患者中,Th17与Th1细胞间亦存在显著的正相关性(r=0.61,P<0.05),但Th17与Tc1细胞间无相关性。
4、慢加急性乙型病毒性肝炎患者血浆中IFN-γ和IL-17表达水平与正常对照相比均无显著性差异。
结论
我们的研究结果进一步表明,在慢加急性乙型病毒性肝炎的异常免疫反应中,Th1和Tc1型免疫反应占优势地位,并且Tc1细胞在慢加急性乙型病毒性肝炎的发病中可能发挥了细胞毒作用和免疫调节的双重作用。尤为重要的是,我们研究首次表明,在慢加急性乙型病毒性肝炎发生和发展中,Th17细胞亚群比例增加可能是一个重要的决定因素,其与Th1和Tc1细胞协同在慢加急性乙型病毒性肝炎的发生、发展中发挥了重要的作用,调节慢加急性乙型病毒性肝炎患者中Th17细胞的异常可能成为慢加急性乙型病毒性肝炎治疗的新策略。
第一部分IMPLICATION OF TH17 AND TH1 CELLS IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS B
Background Hepatitis B virus (HBV) infection is a major public health threat in the world, especially in China. Globally, there are approximately 350 million carriers of HBV, of whom 0.5-1.0 million die due to the HBV-associated liver disease each year. Both CD4+(Th) and CD8+(Tc) T lymphocytes can be functionally divided into type 1(T1) and type 2(T2) subsets based on the secretion of either IFN-γ(T1) or IL-4 (T2). Recent studies have provided compelling evidence for a third CD4+ T cell effector subset besides the well-described Th1 and Th2 CD4+ T cell. The newly identified CD4+ T effector cells have been named as Th17 cells. These cells are characterized as preferential producers of IL-17A (also known as IL-17), IL-17F, IL-21, IL-22, and IL-26 in humans. Retinoid orphan nuclear receptor (RORC), which encodes the human ortholog of mouse RORct, is a key regulator of Th17-cell lineage differentiation. Th17 cells and their effector cytokines are increasingly being recognized as key determinant in the induction of autoimmune diseases and malignant tumor as well as alcoholic liver disease. There are limited data to date about Th17 levels in patients with chronic hepatitis B (CHB).To further investigate the role of Th17 and Thl cells, as well as their relationship in the pathogenesis of CHB, we examined the frequency of Th17 and Thl cells in CHB active patients through intracellular cytokines analysis by flow cytometry, ELISA and real-time PCR.
Objective The pathogenesis of hepatitis B virus (HBV) associated chronic liver disease is still not fully understood.The immune imbalance of cytokine profile exerts a profound influence on the resolution of HBV infections and HBV clearance. This present study aimed to evaluate the immune status of the peripheral T helper (Th) 17 and Th1 cells in the active patients with chronic HBV infection.
Methods Thirty patients with chronic active hepatitis B were included in our present study. The frequency of peripheral Th 17 cells (CD3+CD8-IL-17+T cells), Thl cells (CD3+CD8-IFN-γ+T cells), and Tc1 cells (CD3+CD8+IFN-γ+T cells) in chronic hepatitis B(CHB) were analyzed by flow cytometry. The protein and mRNA levels of interleukin-17 (IL-17) and interferongamma (IFN-γ) were measured by enzyme-linked immunosorbent assay and quantitative real-time polymerase chain reaction (PCR).
Results The percentage of Th17 cells in peripheral blood of CHB patients (1.53±0.52%) was significantly increased than that in normal controls (0.92±0.20%; P<0.05). In contrast, the percentage of Th1 and Tc1 cells of CHB patients was significantly decreased as compared with that of control group. The frequency of Th17 cells had a negative correlation with Th1 cells, and a positive correlation with serum alanine aminotransferase in CHB patients.
Conclusion Our study data strongly support a high Th1 and Tc1 polarization of the immune response in CHB and CTL-mediated cytotoxicity is an alternative mechanism in CHB. More important, our study demonstrates for the first time that Th17 may be an important determinant in the evolution of CHB along with Th1 and Tc1, suggesting that blocking the abnormality of Th17 cell in CHB is likely a promising therapeutic concept for CHB.
第二部分IMPLICATION OF TH17 AND TH1 CELLS IN PATIENTS WITH ACUTE-ON-CHRONIC HEPATITIS B VIRUS LIVER FAILURE
Background Hepatitis B virus (HBV) infection still poses a major public health threat in a large part of the world. Some CHB patients may rapidly progress towards liver failure, a condition referred to as acute-on-chronic liver failure(ACLF). In China, acute-on-chronic hepatitis B liver failure (ACHBLF) accounts for more than 80% of ACLF cases due to a high incidence of HBV infection. ACLF shares striking similarities with septic shock with regard to the features of systemic inflammation, progression to multiple organ dysfunction and functional immunoparesis.The precise mechanisms underlying the deterioration of liver function occurring in ACLF remain unclear.There are limited data to date about Th17 levels in patients with acute-on-chronic hepatitis B liver failure (ACHBLF).To further investigate the role of Th17 and Thl cells, as well as their relationship in the pathogenesis of ACHBLF, we examined the frequency of Th17 and Th1 cells in ACHBLF active patients through intracellular cytokines analysis by flow cytometry and ELISA.
Objective Acute-on-chronic hepatitis B virus liver failure (ACHBLF) has been shown to carry poor prognosis, however, the pathogenesis of ACHBLF is still not fully understood. This present study aimed to evaluate the immune status of the peripheral T helper (Th) 17 and Thl cells in the active patients with ACHBLF.
Methods Twenty patients with ACHBLF were included in our present study. We examined the levels of Th17,Th1 and Tc1 cells in peripheral blood which was activated in vitro by PMA/ionomycin in short-term cultures in ACHBLF patients and controls by flow cytometry through intracellular cytokines analysis. Th17 cells and Thl cells were identified as those that were CD3+CD8-IL-17A+and CD3+CD8-IFN-γ+, and Tc1 cells were those that were CD3+CD8+IFN-γ+. ELISA was used to detect the expression of Th1 and Th17 cytokines (IFN-γand IL-17) in plasma.
Results The results showed that the percentages of both Thl and Tc1 cells in ACHBLF patients increased significantly compared with the normal controls (P<0.01 for Thl, P<0.05 for Tc1). More importantly, the percentage of Th17 in patients with ACHBLF was markedly higher than that of normal controls (P＜0.05). Also, the percentage of Th17 cells positively correlated with Thl cells (r=0.61, P＜0.05). There was no significant correlation between Th17 and Tc1 cells (r=0.09, P=0.71).
Conclusion Our study demonstrates for the first time that Th17 cells may be an important determinant in the evolution of ACHBLF along with Thl cells, suggesting that blocking the abnormality of Th17 cell in ACHBLF is likely a promising therapeutic concept for ACHBLF.
慢性乙型肝炎的发病机制十分复杂,宿主免疫调节的紊乱是导致病毒不能有效清除、病情迁延不愈、引起慢性炎症、造成肝脏病变的重要原因。许多研究表明Th1、Th2细胞亚群的比例失衡、功能失调是导致慢性乙肝发病的重要因素。传统上,CD4+辅助T细胞(Th)和CD8+细胞毒性T细胞(Tc)根据各自分泌的细胞因子的不同,可以将T细胞分为两类：Ⅰ类T细胞(Th1和Tc1,合称T1)和Ⅱ类T细胞(Th2和Tc2,合称T2),前者主要分泌干扰素γ(IFN-γ)、白细胞介素(IL)-2、肿瘤坏死因子(TNF)-β,后者主要分泌IL-4、IL-5、IL-6、IL-10和IL-13,并且常以IFN-γ/IL-4代表T1／T2的比例。T1和T2在免疫调节中均发挥重要作用,它们各自分泌的细胞因子对免疫应答效应起关键作用。CD8+T细胞可分为Tc1和Tc2两个细胞亚群,Tc1与Th1亚群相似,可分泌IL-2、IFN-γ等细胞因子并且可发挥细胞毒作用。
Th17细胞是最近发现的一种新的效应性CD4+T细胞亚群,以产生分泌白介素17(IL-17)为特征。Th17细胞与Th1和Th2细胞无论在分化途径、信号转导还是生物学功能等方面均有所不同。大量证据表明Th17细胞通过产生IL-17作用于不同的靶细胞,诱导其他细胞因子产生,参与细胞因子网络调节,触发炎症递质释放,从而介导炎性反应(防御胞外病原菌的感染)、自身免疫性疾病、肿瘤和移植排斥等病理状态的发生和发展。迄今为止,有关慢性乙型肝炎患者外周血中Th17细胞的研究报道很少。
目的
本研究的目的是通过对慢性乙型肝炎患者外周血Th17、Th1和Tc1细胞亚群及血浆细胞因子的检测,进一步探讨三种细胞亚群在慢性乙型肝炎患者发病机制中的作用及评价它们的临床相关性。
方法
应用三色流式细胞术检测慢性乙型肝炎患者和正常对照外周血中Th1、Th17和Tc1细胞占CD3+T细胞的比例。三种细胞亚群的界定分别为：Th17细胞为CD3+CD8-IL-17A+,Th1细胞为CD3+CD8-IFN-γ+,Tc1细胞为CD3+CD8+IFN-γ+；应用ELISA技术检测慢性乙型肝炎患者和正常对照血浆中IL-17和IFN-γ的表达水平。应用逆转录聚合酶链反应(RT-PCR)方法检测IL-17及IFN-γ在慢性乙型肝炎患者和正常对照外周血单个核细胞中的表达。
结果
1、慢性乙型肝炎患者外周血Th1细胞的比例(8.55±1.53％)明显低于正常对照组(10.56±1.91％)(P<0.01),并且慢性乙型肝炎患者Tc1细胞的比例(6.35±1.85％)较正常对照组(9.0±2.79％)亦显著降低(P<0.05)。
2、慢性乙型肝炎患者Th17细胞的比例(1.53±0.52％)较正常对照(0.92±0.20％)显著升高(P<0.05)。
3、在慢性乙型肝炎患者中,Th1与Tc1细胞间存在明显的正相关性(r=0.58,P<0.05),Th17与Thl细胞间亦存在显著的负相关性(r=-0.56,P<0.05),但Th17与Tc1细胞间无相关性。
4、慢性乙型肝炎患者血浆中IFN-γ和IL-17表达水平与正常对照相比均无显著性差异。
5、在慢性乙型肝炎患者中,外周血中Th17细胞亚群的比例与ALT呈明显正相关(r=0.66,P<0.05)。慢性乙型肝炎患者外周血中Th1细胞亚群的比例与ALT呈显著负相关(r=-0.68,P<0.05)。
结论
我们的研究结果进一步表明,在慢性乙型肝炎的异常免疫反应中,Th1和Tc1型免疫反应受到抑制。尤为重要的是,我们研究首次表明,在慢性乙型肝炎发生和发展中,Th17细胞亚群比例增加可能是一个重要的决定因素,调节慢性乙型肝炎患者中Th17细胞的异常可能成为慢性乙型肝炎治疗的新策略。
第二部分Th17、Th1和Tc1细胞亚群在慢加急性重型乙型病毒性肝炎患者中的变化及意义
HBV感染可引起人类急慢性肝炎,与肝硬化和肝细胞癌的发生和发展密切相关,我国是乙型肝炎的高发区,在全球3.5亿HBV携带者中,约9300万,发展为慢性乙型肝炎的患者大约有2500万,其中每年约有1％的乙型肝炎患者发展为重型肝炎。重型肝炎(肝衰竭)可被分为四类：急性肝衰竭(acute liver failure, ALF)、亚急性肝衰竭(subacute liver failure, SALF)、慢加急性肝衰竭(acute-on-chronic liver failure, ACLF)和慢性肝衰竭(chronic liver failure, CLF)、慢加急性肝衰竭是在慢性肝病基础上出现的急性肝脏功能失代偿。
在我们的第一部分实验中,我们已经发现慢性乙型肝炎患者外周血中Th1,Tc1细胞的比例明显低于正常对照。提示患者细胞免疫功能低下,不能有效清除体内的HBV,使HBV持续感染形成慢性化。Th17细胞亚群比例增加可能是一个重要的决定因素。
在我国,慢性乙型病毒性肝炎是引起慢加急性肝衰竭的主要病因,有报道称CHB占ACLF所有病因的80％。由慢性乙型病毒性肝炎所致的慢加急性肝衰竭又称为慢加急性重型乙型病毒性肝炎(ACHBLF)。ACHBLF进展迅速,病情凶险,临床上缺乏特异、有效的治疗手段,绝大部分患者预后较差,易出现各种并发症而危及患者的生命,虽然近年来在ACHBLF的发病机制、临床诊断、治疗等方面取得了很大的进展,但死亡率仍高达50％-60％。目前,慢性乙型肝炎出现急性肝功能失代偿引起ACHBLF精确机制尚不明确,明确其发病机制必将提高ACHBLF的治疗水平,降低其死亡率。
目的
本研究的目的是通过对慢加急性乙型病毒性肝炎患者外周血Th17、Th1和Tc1细胞亚群及血浆细胞因子的检测,进一步探讨三种细胞亚群在慢加急性乙型病毒性肝炎患者发病机制中的作用。
方法
应用三色流式细胞术检测慢加急性乙型病毒性肝炎患者和正常对照外周血中Th1、Th17和Tc1细胞占CD3+T细胞的比例。三种细胞亚群的界定分别为：Th17细胞为CD3+CD8-IL-17A+,Th1细胞为CD3+CD8-IFN-γ+,Tc1细胞为CD3+CD8+IFN-γ+；应用ELISA技术检测慢加急性乙型病毒性肝炎患者和正常对照血浆中IL-17和IFN-γ的表达水平。
结果
1、慢加急性乙型病毒性肝炎患者外周血Th1细胞的比例(8.55±1.53％)明显低于正常对照组(10.56±1.91％)(P<0.01),并且慢加急性乙型病毒性肝炎患者Tc1细胞的比例(6.35±1.85％)较正常对照组(9.0±2.79％)亦显著升高(P<0.05)。
2、慢加急性乙型病毒性肝炎患者Th17细胞的比例(1.53±0.52％)较正常对照(0.92±0.20％)显著升高(P<0.05)。
3、在慢加急性乙型病毒性肝炎患者中,Th17与Th1细胞间亦存在显著的正相关性(r=0.61,P<0.05),但Th17与Tc1细胞间无相关性。
4、慢加急性乙型病毒性肝炎患者血浆中IFN-γ和IL-17表达水平与正常对照相比均无显著性差异。
结论
我们的研究结果进一步表明,在慢加急性乙型病毒性肝炎的异常免疫反应中,Th1和Tc1型免疫反应占优势地位,并且Tc1细胞在慢加急性乙型病毒性肝炎的发病中可能发挥了细胞毒作用和免疫调节的双重作用。尤为重要的是,我们研究首次表明,在慢加急性乙型病毒性肝炎发生和发展中,Th17细胞亚群比例增加可能是一个重要的决定因素,其与Th1和Tc1细胞协同在慢加急性乙型病毒性肝炎的发生、发展中发挥了重要的作用,调节慢加急性乙型病毒性肝炎患者中Th17细胞的异常可能成为慢加急性乙型病毒性肝炎治疗的新策略。
第一部分IMPLICATION OF TH17 AND TH1 CELLS IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS B
Background Hepatitis B virus (HBV) infection is a major public health threat in the world, especially in China. Globally, there are approximately 350 million carriers of HBV, of whom 0.5-1.0 million die due to the HBV-associated liver disease each year. Both CD4+(Th) and CD8+(Tc) T lymphocytes can be functionally divided into type 1(T1) and type 2(T2) subsets based on the secretion of either IFN-γ(T1) or IL-4 (T2). Recent studies have provided compelling evidence for a third CD4+ T cell effector subset besides the well-described Th1 and Th2 CD4+ T cell. The newly identified CD4+ T effector cells have been named as Th17 cells. These cells are characterized as preferential producers of IL-17A (also known as IL-17), IL-17F, IL-21, IL-22, and IL-26 in humans. Retinoid orphan nuclear receptor (RORC), which encodes the human ortholog of mouse RORct, is a key regulator of Th17-cell lineage differentiation. Th17 cells and their effector cytokines are increasingly being recognized as key determinant in the induction of autoimmune diseases and malignant tumor as well as alcoholic liver disease. There are limited data to date about Th17 levels in patients with chronic hepatitis B (CHB).To further investigate the role of Th17 and Thl cells, as well as their relationship in the pathogenesis of CHB, we examined the frequency of Th17 and Thl cells in CHB active patients through intracellular cytokines analysis by flow cytometry, ELISA and real-time PCR.
Objective The pathogenesis of hepatitis B virus (HBV) associated chronic liver disease is still not fully understood.The immune imbalance of cytokine profile exerts a profound influence on the resolution of HBV infections and HBV clearance. This present study aimed to evaluate the immune status of the peripheral T helper (Th) 17 and Th1 cells in the active patients with chronic HBV infection.
Methods Thirty patients with chronic active hepatitis B were included in our present study. The frequency of peripheral Th 17 cells (CD3+CD8-IL-17+T cells), Thl cells (CD3+CD8-IFN-γ+T cells), and Tc1 cells (CD3+CD8+IFN-γ+T cells) in chronic hepatitis B(CHB) were analyzed by flow cytometry. The protein and mRNA levels of interleukin-17 (IL-17) and interferongamma (IFN-γ) were measured by enzyme-linked immunosorbent assay and quantitative real-time polymerase chain reaction (PCR).
Results The percentage of Th17 cells in peripheral blood of CHB patients (1.53±0.52%) was significantly increased than that in normal controls (0.92±0.20%; P<0.05). In contrast, the percentage of Th1 and Tc1 cells of CHB patients was significantly decreased as compared with that of control group. The frequency of Th17 cells had a negative correlation with Th1 cells, and a positive correlation with serum alanine aminotransferase in CHB patients.
Conclusion Our study data strongly support a high Th1 and Tc1 polarization of the immune response in CHB and CTL-mediated cytotoxicity is an alternative mechanism in CHB. More important, our study demonstrates for the first time that Th17 may be an important determinant in the evolution of CHB along with Th1 and Tc1, suggesting that blocking the abnormality of Th17 cell in CHB is likely a promising therapeutic concept for CHB.
第二部分IMPLICATION OF TH17 AND TH1 CELLS IN PATIENTS WITH ACUTE-ON-CHRONIC HEPATITIS B VIRUS LIVER FAILURE
Background Hepatitis B virus (HBV) infection still poses a major public health threat in a large part of the world. Some CHB patients may rapidly progress towards liver failure, a condition referred to as acute-on-chronic liver failure(ACLF). In China, acute-on-chronic hepatitis B liver failure (ACHBLF) accounts for more than 80% of ACLF cases due to a high incidence of HBV infection. ACLF shares striking similarities with septic shock with regard to the features of systemic inflammation, progression to multiple organ dysfunction and functional immunoparesis.The precise mechanisms underlying the deterioration of liver function occurring in ACLF remain unclear.There are limited data to date about Th17 levels in patients with acute-on-chronic hepatitis B liver failure (ACHBLF).To further investigate the role of Th17 and Thl cells, as well as their relationship in the pathogenesis of ACHBLF, we examined the frequency of Th17 and Th1 cells in ACHBLF active patients through intracellular cytokines analysis by flow cytometry and ELISA.
Objective Acute-on-chronic hepatitis B virus liver failure (ACHBLF) has been shown to carry poor prognosis, however, the pathogenesis of ACHBLF is still not fully understood. This present study aimed to evaluate the immune status of the peripheral T helper (Th) 17 and Thl cells in the active patients with ACHBLF.
Methods Twenty patients with ACHBLF were included in our present study. We examined the levels of Th17,Th1 and Tc1 cells in peripheral blood which was activated in vitro by PMA/ionomycin in short-term cultures in ACHBLF patients and controls by flow cytometry through intracellular cytokines analysis. Th17 cells and Thl cells were identified as those that were CD3+CD8-IL-17A+and CD3+CD8-IFN-γ+, and Tc1 cells were those that were CD3+CD8+IFN-γ+. ELISA was used to detect the expression of Th1 and Th17 cytokines (IFN-γand IL-17) in plasma.
Results The results showed that the percentages of both Thl and Tc1 cells in ACHBLF patients increased significantly compared with the normal controls (P<0.01 for Thl, P<0.05 for Tc1). More importantly, the percentage of Th17 in patients with ACHBLF was markedly higher than that of normal controls (P＜0.05). Also, the percentage of Th17 cells positively correlated with Thl cells (r=0.61, P＜0.05). There was no significant correlation between Th17 and Tc1 cells (r=0.09, P=0.71).
Conclusion Our study demonstrates for the first time that Th17 cells may be an important determinant in the evolution of ACHBLF along with Thl cells, suggesting that blocking the abnormality of Th17 cell in ACHBLF is likely a promising therapeutic concept for ACHBLF.
引文
1 Word Health Organization.Hepatitis B.World Health Organization Fact Sheet 204 dex.(Revised October 2000). WHO Web site, http://www.who.int/mediacentre/ factsheets/fs204/en/in html.
2梁晓峰,陈园生,王晓军,等.中国3岁以上人群乙型肝炎血清流行病学研究.中华流行病学杂志.2005；26：655-658.
3 Trinchieri G.Interleukin-12:a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity[J].Annu Rev Immuno;1995.13(4):251.
4 Mosmann TR, Sad S. The expanding universe of T-cell subsets:Th1, Th2 and more[J]. Immunol Today.1996;17:138-46.
5 Maini M K, Boni C, Ogg G S, et al.Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection[J].Gastroenterology.1999;117(6):1386-1396.
6 Webster G J,Bertoletti A.Control or persistence of hepatitis B virus:the critical role of initial host-virus interactions[J].Immtmol Cell Biol.2002;80(1):101-105.
7 Maini M K,Boni C,Lee C K,et al.The role of virus-specific CD8+cells in liver damage and viral control during persistent hepatitis B virus infection[J].J EXP Med,2000;191(8):1269-1280.
8 Liblau RS, Singer SM, McDevitt HO.Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases[J]. Immunol Today.1995; 16: 34-8.
9 Romagnani S. Th1 and Th2 in human diseases[J]. Clin Immunol Immunopathol. 1996; 80:225-35.
10 Croft M, CarterL, Swain SL, et al. Generation of polarized antigen-specific CD8 effector populations:recip rocal action of interleukin(IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles[J]. J Exp Med.1994;180:1715-28.
11 Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura[J]. Haematologica.2005;90: 914-23.
12 Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases[J]. Clin Microbiol Rev. 1996; 9:532-62.
13赵爽,颜学兵,王金章,郝俊贵,汪明珊,冯霞,万美容.慢性乙型肝炎外周血细胞毒性T细胞亚群(Tc1／Tc2)失衡的研究.临床肝胆病杂志.2008；24：417-19.
14 Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J]. Nat Immunol.2005; 6:1133-41.
15 Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol.2005; 6:1123-32.
16 Kolls JK, Linden A. Interleukin-17 family members and inflammation[J]. Immunity.2004; 21:467-76.
17 Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM. TH-17 cells in rheumatoid arthritis[J]. Arthritis Res Ther.2008;10:R93.
18 Pelchen-Matthews A, Parsons IJ, Marsh M. Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p561ck, increased association with clathrin-coated pits, and altered endosomal sorting[J]. J Exp Med. 1993; 178:1209-22.
19 Marcellin P,Asselah T,Boyer N.Treatment of chronic hepatitis B Rev Prat.2005;55(6):624-32.
20 Matthews GV,Nelson MR.The management of chronic hepatitis B infection. Int J STD AIDS.2001;12(6):353-7.
21 Luca G, Guidotti, Francis V Chisari.Immunobiology and pathogenesis of viral hepatitis.Annu.Rev.Pathol.Mech.Dis.2006;1:23-61.
22 Chisari FV, Ferrari C.Hepatitis B virus immunopathogenesis.Annu Rev Immunol.1995; 13:29-60.
23 Barbara Rehermann and Michelina Nascimbeni.Immunology of hepatitis B virus and hepatitis C virus infection.Nature Reviews Immunology.2005;5:215-229.
24 Yao Z, Painter S L, Fanslow W C, et al. Human IL-17:a novel cytokine derived from T cells [J]. J Immunol.1995; 155:5483-6.
25 LaanM, Lotvall J, Chung KF, et al. IL-17-induced cytokine release in human bronchial ep ithelial cells in vitro:role of mitogen-activated protein (MAP) kinases[J]. B r J Pharmacol.2001; 133:200-6.
26 Yao, Z, Fanslow, WC,Seldin, MF, et al. Herpesvirus saimiri encodes a new cytokine,IL-17,which binds to novel cytokine receptor. Immuity.1995;3:811-821.
27 Fossiez F,Djossou O,Chomarat P,et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.J Exp Med.1996;183:2593-2603.
28 Moseley TA,Haudenschild DR,Rose L,etal.Interleukin-17 family and IL-17 receptors.Cytokine Growth Factor Rev.2003;14:155-174.
29 Kolls JK,and Linden A. Interleukin-17 family members and inflammation. Immunity.2004;21:467-476.
30 Aggarwal S,Gurney AL. IL-17:Prototype member of an emerging cytokine family. J.Leukoc.Biol.2002;71:1-8.
31 Hymowitz SQFilvaroff EH, Yin JP,etal.IL-17s adopt a cystine knot fold:structure and activity of a novel cytokine, IL-17F,and implications for receptor binding.EMBO J.2001;20:5332-5341.
32 Molet S,Hamid Q,Davoine F,et al.IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J.Allergy Clin. Immunol.2001;108:430-438.
33 Awane M, Andres PG,Li DJ,te al. NF-kappa B-inducing kinase is a common mediator of IL-17,TNF-alpha,and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells.J.Immunol,1999,162:5337-5344.
34 Yao,Z,Fanslow,WC,Seldin,MF,et al.Herpes virus saimiri encodes a new cytokine,IL-17,which binds to novel cytokine receptor.Immunity.1995;3:811-821.
35 Ferretti S,Bonneau O,dubois GR,et al.IL-17,produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia:IL-15 as a possible trigger.J.Immunol.2003; 170:2106-2112
36 Happel KI,Zheng M,Young E,et al.Cuting edge:roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.J.Immunol.2003;170:4432-4436.
37 Miossec P.Interleukin-17 in rheumatoid arthritis:if T cells were to contribute to inflammation and destruction through synergy.Arthritis Rheum,2003;48:594-601.
38张景熙.IL-17的研究进展.国外医学免疫学分册.2003；26：315-318.
39 Ivanov II,Mckenzie BS,Zhou L,et al.The Orphan Nuclear Receptor ROR γ t Directs the Differentiation Program of Proinflammatory IL-1 7+ T Helper Cells.Cell.2006;126:1121-1133.
40 Mangan PR,Harrington LE,O'Quinn DB,et al. Transforming growth factor-β induces development of the TH 1 7 lineage.Nature.2006;441:231-234.
41 Nurieva R,Yang XO Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatoy T cells.Nature.2007;448:480-483.
42 Bettelli E,Oukka M,Kuchroo VK.TH-17 cells in the circle of immunity and autoimmunity.Nature Immunology.2007; 8:345-350.
43张风蕴,徐红薇,任欢.Th17细胞的生物学特性.国际免疫学杂志.2007；30：292-295.
44 Arian Laurence,Cristina M,Todd S,et al. Interleukin-2 signaling via STAT5 constrains generation. Immunity.2007;26:371-381.
45 Kryczek I,Wei S,Zou L,et al. Cutting edge:Th1 7 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J.Immunol,2007; 1 78:6730-6733.
46 Schnyder B,Schnyder-Candrian S,Pansky A,et al. IL-1 7 reduces TNF-induced Rantes and VCAM-1 expression.Cytokine.2005;31:191-202.
47 Komiyama Y Nakae S,Matsuki T,et al. IL-1 7 plays an important role in the development of experimental autoimmune encephalomyelitis.J Immunol.2006; 177:566-573.
48 Chen Y, Thai P,Zhao YH,et al.Stimulation of airway mucin gene expression by interleukin(IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem.2003;278:17036-17043.
49 Wong CK,Ho CY, Li EK,et al.Elevation of prolnflammatory cytokine(IL-18,IL-1 7,IL-12)and Th2 cytokine(IL-4) concentrations in patients with systemic lupus Erythematosus.Lupus.2000;9:589-593.
50 McKenzie BS,Kastelein RA,Cua DJ. Understanding the IL-23-IL-17 immune pathway.Trends Immunol.2006;27:17-23.
51 Stoop JN,van der Molen RG,Baan CC,etal.Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology.2005;41(4):771-778.
52 Korn T, Bettelli E, Gao W. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells[J]. Nature.2007;448:484-8.
53 Fantini M C, Rizzo A, Fina D, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells [J]. Eur J Immunol.2007;37.
54 Keefe D, Shi L, Feske S, Massol R, Navarro F, Kirchhausen T, Lieberman J. Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity.2005; 23:249-262
55欧国生.类风湿性关节炎患者Th1／Th2、Te1／Tc2细胞的检测及意义.实用医技杂志.2006；13：849-51.
56 Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, Noble A, Kemeny DM. Human Tel and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes[J]. Blood.2000;95:231-40.
1 Lok AS,Mcmahon BJ. Chronic hepatitis B[J]. Hepatology.2007;45(2):507-539.
2庄辉.乙型肝炎流行病学研究进展国外医学流行病学.传染病学分册.2004；31(3)：133-135.
3中华医学会感染病分会肝衰竭及人工肝学组.中华医学会肝病分会重型肝病与人工肝学组.肝衰竭诊疗指南.中华肝脏病杂志.2006；14(9)：643-646.
4 Shiv Kumar Sarin, Ashish Kumar, John A. Almeida, et al. Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatology.2009;3:269-282.
5医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南.中华流行病学杂志.2006；27：79-88.
6 Zou Z, Chen J, Xin S, Xing H, Li B, Li J, et al. Features of onset of chronic severe hepatitis in 520 cases. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi.2002; 16:322-325.
7 Sen S, Mohensi S, Sjodin L, Cheshire L, Williams R, Bjornsson E, Jalan R: Baseline SOFA score and its lack of early improvement accurately predicts mortality in patients with acute-on-chronic liver failure. Hepatology.2004, 40(11):489A.
8 Stauber R, Stadlbauer V, Struber G, Kaufinann P:Evaluation of four prognostic scores in patients with acute-on-chronic liver failure. J Hepatol.2006; 44:69-70.
9 Akpolat N, Yahsi S, Godekmerdan A, et al. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol.2005;11:3260-3.
11 Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA.1990; 87(17):6599-603.
11 Chen M, Sallberg M, Hughes J, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol.2005;79(5):3016-27.
12 Chen MT, Billaud JN, Sallberg M, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA.2004;101(41):14913-8.
13 Reignat S, Webster GJ, Brown D, et al. Escaping high viral load exhaustion:CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med.2002;195(9):1089-101.
14 Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8t T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B:implications for immunotherapy. J Virol. 2004;78(11):5707-19.
15 Vierling JM. The immunology of hepatitis B. Clin Liver Dis.2007;11:727-59, vii-viii.
16 Ferrari C, Missale G, Boni C, et al. Immunopathogenesis of hepatitis B. J Hepatol.2003;39 Suppl 1:S36-42.
17 Kondo Y, Kobayashi K, Ueno Y, et al. Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J Gastroenterol.2006; 12:4310-7.
18覃小敏,宁琴.重型肝炎发病的分子机制研究进展.国外医学.流行病学传染病学分册.2004；31(3)：150-154.
19 Imamum T,Yokosuka O,Kurihara T,et al.Distribution of hepatitisB viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan.Gut.2003;52(11):1630-1637.
20 Hou JL, Lin Y, Waters J, et al. Detection and significance of a G1862T Variant of hepatitis B virus in Chinese patients with fulminant hepatitis.J Gen Virol. 2002;83:2291-2298.
21 Ando K, Moriyanra T, Guidoti LG, et al. Mechanisms of class I restricted imnamopathology.A trensgenic mouse model of fulminant hepatitis.J Exp Med.1993;178(5):1541-1554.
22 Liblau RS, Singer SM, McDevitt HO.Thl and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases[J]. Immunol Today.1995; 16: 34-8.
23 Romagnani S. Th1 and Th2 in human diseases[J]. Clin Immunol Immunopathol. 1996; 80:225-35.
24赵爽,颜学兵,王金章,郝俊贵,汪明珊,冯霞,万美容.慢性乙型肝炎外周血细胞毒性T细胞亚群(Tc1／Tc2)失衡的研究.临床肝胆病杂志,2008；24：417-19.
25欧国生.类风湿性关节炎患者Th1／Th2、Tc1／Tc2细胞的检测及意义.实用医技杂志,2006；13：849-51.
26 Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity[J]. Nat Immunol.2007;8:345-50
27 Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature.2006 May 11;441(7090):235-8.
28 Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells. Cell.2006 Sep 22;126(6):1121-33.
29 Semple JW, Milev Y, Cosgrave D,Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura:relationship to platelet phenotype and antiplatelet T-cell reactivity[J]. Blood.1996;87:4245-54.
30 Ogawara H, Handa H, Morita K, Hayakawa M, Kojima J, Amagai H, et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura[J]. Eur J Haematol.2003;71:283-8.
31 Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response[J].Blood.2004; 103:2645-7.
1 Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med, 1996,183:2593-603.
2 Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev,2003,14:155-74.
3 Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity, 2004,21:467-76.
4 Aggarwal S, Gurney AL. IL-17:prototype member of an emerging cytokine family. J Leukoc Biol,2002,71:1-8.
5 Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J,2001,20:5332-41.
6 Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol, 2001,108:430-8.
7 Awane M, Andres PG, Li DJ, et al. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol,1999,162:5337-44.
8 Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity,1995,3:811-21.
9孙创斌胡晋红朱全刚刘继勇刘艳霞.药物作用新靶点：白细胞介素17及其受体.国际药学研究杂志,2008,3：169-172.
10 Miossec P. Interleukin-17 in rheumatoid arthritis:if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum,2003,48:594-601.
11张景熙.IL-17的研究进展.国外医学免疫学分册,2003,6：315-318.
12 Sylvester J, Liacini A, Li WQ, et al. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3,-13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal,2004,16:469-76.
13 Kim KW, Cho ML, Park MK, et al. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther,2005,7:R1 39-48.
14 Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis:lessons from animal models. Arthritis Res Ther, 2005,7:29-37.
15 Nielsen OH, Kirman I, Rudiger N, et al. Upregulation of interleukin-12 and-17 in active inflammatory bowel disease. Scand J Gastroenterol,2003,38:180-5.
16 Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut,2003,52:65-70.
17唐碧霞,张炬,唐福林.IL-17与自身免疫性疾病关系的研究进展.基础医学与临床,2008,28：94-97.
18 Yasumi Y, Takikawa Y, Endo R, et al. Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol Res,2007,37:248-54.
19 Loong CC, Hsieh HG, Lui WY, et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol, 2002,197:322-32.
2梁晓峰,陈园生,王晓军,等.中国3岁以上人群乙型肝炎血清流行病学研究.中华流行病学杂志.2005；26：655-658.
3 Trinchieri G.Interleukin-12:a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity[J].Annu Rev Immuno;1995.13(4):251.
4 Mosmann TR, Sad S. The expanding universe of T-cell subsets:Th1, Th2 and more[J]. Immunol Today.1996;17:138-46.
5 Maini M K, Boni C, Ogg G S, et al.Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection[J].Gastroenterology.1999;117(6):1386-1396.
6 Webster G J,Bertoletti A.Control or persistence of hepatitis B virus:the critical role of initial host-virus interactions[J].Immtmol Cell Biol.2002;80(1):101-105.
7 Maini M K,Boni C,Lee C K,et al.The role of virus-specific CD8+cells in liver damage and viral control during persistent hepatitis B virus infection[J].J EXP Med,2000;191(8):1269-1280.
8 Liblau RS, Singer SM, McDevitt HO.Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases[J]. Immunol Today.1995; 16: 34-8.
9 Romagnani S. Th1 and Th2 in human diseases[J]. Clin Immunol Immunopathol. 1996; 80:225-35.
10 Croft M, CarterL, Swain SL, et al. Generation of polarized antigen-specific CD8 effector populations:recip rocal action of interleukin(IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles[J]. J Exp Med.1994;180:1715-28.
11 Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura[J]. Haematologica.2005;90: 914-23.
12 Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases[J]. Clin Microbiol Rev. 1996; 9:532-62.
13赵爽,颜学兵,王金章,郝俊贵,汪明珊,冯霞,万美容.慢性乙型肝炎外周血细胞毒性T细胞亚群(Tc1／Tc2)失衡的研究.临床肝胆病杂志.2008；24：417-19.
14 Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J]. Nat Immunol.2005; 6:1133-41.
15 Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol.2005; 6:1123-32.
16 Kolls JK, Linden A. Interleukin-17 family members and inflammation[J]. Immunity.2004; 21:467-76.
17 Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM. TH-17 cells in rheumatoid arthritis[J]. Arthritis Res Ther.2008;10:R93.
18 Pelchen-Matthews A, Parsons IJ, Marsh M. Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p561ck, increased association with clathrin-coated pits, and altered endosomal sorting[J]. J Exp Med. 1993; 178:1209-22.
19 Marcellin P,Asselah T,Boyer N.Treatment of chronic hepatitis B Rev Prat.2005;55(6):624-32.
20 Matthews GV,Nelson MR.The management of chronic hepatitis B infection. Int J STD AIDS.2001;12(6):353-7.
21 Luca G, Guidotti, Francis V Chisari.Immunobiology and pathogenesis of viral hepatitis.Annu.Rev.Pathol.Mech.Dis.2006;1:23-61.
22 Chisari FV, Ferrari C.Hepatitis B virus immunopathogenesis.Annu Rev Immunol.1995; 13:29-60.
23 Barbara Rehermann and Michelina Nascimbeni.Immunology of hepatitis B virus and hepatitis C virus infection.Nature Reviews Immunology.2005;5:215-229.
24 Yao Z, Painter S L, Fanslow W C, et al. Human IL-17:a novel cytokine derived from T cells [J]. J Immunol.1995; 155:5483-6.
25 LaanM, Lotvall J, Chung KF, et al. IL-17-induced cytokine release in human bronchial ep ithelial cells in vitro:role of mitogen-activated protein (MAP) kinases[J]. B r J Pharmacol.2001; 133:200-6.
26 Yao, Z, Fanslow, WC,Seldin, MF, et al. Herpesvirus saimiri encodes a new cytokine,IL-17,which binds to novel cytokine receptor. Immuity.1995;3:811-821.
27 Fossiez F,Djossou O,Chomarat P,et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.J Exp Med.1996;183:2593-2603.
28 Moseley TA,Haudenschild DR,Rose L,etal.Interleukin-17 family and IL-17 receptors.Cytokine Growth Factor Rev.2003;14:155-174.
29 Kolls JK,and Linden A. Interleukin-17 family members and inflammation. Immunity.2004;21:467-476.
30 Aggarwal S,Gurney AL. IL-17:Prototype member of an emerging cytokine family. J.Leukoc.Biol.2002;71:1-8.
31 Hymowitz SQFilvaroff EH, Yin JP,etal.IL-17s adopt a cystine knot fold:structure and activity of a novel cytokine, IL-17F,and implications for receptor binding.EMBO J.2001;20:5332-5341.
32 Molet S,Hamid Q,Davoine F,et al.IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J.Allergy Clin. Immunol.2001;108:430-438.
33 Awane M, Andres PG,Li DJ,te al. NF-kappa B-inducing kinase is a common mediator of IL-17,TNF-alpha,and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells.J.Immunol,1999,162:5337-5344.
34 Yao,Z,Fanslow,WC,Seldin,MF,et al.Herpes virus saimiri encodes a new cytokine,IL-17,which binds to novel cytokine receptor.Immunity.1995;3:811-821.
35 Ferretti S,Bonneau O,dubois GR,et al.IL-17,produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia:IL-15 as a possible trigger.J.Immunol.2003; 170:2106-2112
36 Happel KI,Zheng M,Young E,et al.Cuting edge:roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.J.Immunol.2003;170:4432-4436.
37 Miossec P.Interleukin-17 in rheumatoid arthritis:if T cells were to contribute to inflammation and destruction through synergy.Arthritis Rheum,2003;48:594-601.
38张景熙.IL-17的研究进展.国外医学免疫学分册.2003；26：315-318.
39 Ivanov II,Mckenzie BS,Zhou L,et al.The Orphan Nuclear Receptor ROR γ t Directs the Differentiation Program of Proinflammatory IL-1 7+ T Helper Cells.Cell.2006;126:1121-1133.
40 Mangan PR,Harrington LE,O'Quinn DB,et al. Transforming growth factor-β induces development of the TH 1 7 lineage.Nature.2006;441:231-234.
41 Nurieva R,Yang XO Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatoy T cells.Nature.2007;448:480-483.
42 Bettelli E,Oukka M,Kuchroo VK.TH-17 cells in the circle of immunity and autoimmunity.Nature Immunology.2007; 8:345-350.
43张风蕴,徐红薇,任欢.Th17细胞的生物学特性.国际免疫学杂志.2007；30：292-295.
44 Arian Laurence,Cristina M,Todd S,et al. Interleukin-2 signaling via STAT5 constrains generation. Immunity.2007;26:371-381.
45 Kryczek I,Wei S,Zou L,et al. Cutting edge:Th1 7 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J.Immunol,2007; 1 78:6730-6733.
46 Schnyder B,Schnyder-Candrian S,Pansky A,et al. IL-1 7 reduces TNF-induced Rantes and VCAM-1 expression.Cytokine.2005;31:191-202.
47 Komiyama Y Nakae S,Matsuki T,et al. IL-1 7 plays an important role in the development of experimental autoimmune encephalomyelitis.J Immunol.2006; 177:566-573.
48 Chen Y, Thai P,Zhao YH,et al.Stimulation of airway mucin gene expression by interleukin(IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem.2003;278:17036-17043.
49 Wong CK,Ho CY, Li EK,et al.Elevation of prolnflammatory cytokine(IL-18,IL-1 7,IL-12)and Th2 cytokine(IL-4) concentrations in patients with systemic lupus Erythematosus.Lupus.2000;9:589-593.
50 McKenzie BS,Kastelein RA,Cua DJ. Understanding the IL-23-IL-17 immune pathway.Trends Immunol.2006;27:17-23.
51 Stoop JN,van der Molen RG,Baan CC,etal.Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology.2005;41(4):771-778.
52 Korn T, Bettelli E, Gao W. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells[J]. Nature.2007;448:484-8.
53 Fantini M C, Rizzo A, Fina D, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells [J]. Eur J Immunol.2007;37.
54 Keefe D, Shi L, Feske S, Massol R, Navarro F, Kirchhausen T, Lieberman J. Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity.2005; 23:249-262
55欧国生.类风湿性关节炎患者Th1／Th2、Te1／Tc2细胞的检测及意义.实用医技杂志.2006；13：849-51.
56 Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, Noble A, Kemeny DM. Human Tel and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes[J]. Blood.2000;95:231-40.
1 Lok AS,Mcmahon BJ. Chronic hepatitis B[J]. Hepatology.2007;45(2):507-539.
2庄辉.乙型肝炎流行病学研究进展国外医学流行病学.传染病学分册.2004；31(3)：133-135.
3中华医学会感染病分会肝衰竭及人工肝学组.中华医学会肝病分会重型肝病与人工肝学组.肝衰竭诊疗指南.中华肝脏病杂志.2006；14(9)：643-646.
4 Shiv Kumar Sarin, Ashish Kumar, John A. Almeida, et al. Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatology.2009;3:269-282.
5医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南.中华流行病学杂志.2006；27：79-88.
6 Zou Z, Chen J, Xin S, Xing H, Li B, Li J, et al. Features of onset of chronic severe hepatitis in 520 cases. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi.2002; 16:322-325.
7 Sen S, Mohensi S, Sjodin L, Cheshire L, Williams R, Bjornsson E, Jalan R: Baseline SOFA score and its lack of early improvement accurately predicts mortality in patients with acute-on-chronic liver failure. Hepatology.2004, 40(11):489A.
8 Stauber R, Stadlbauer V, Struber G, Kaufinann P:Evaluation of four prognostic scores in patients with acute-on-chronic liver failure. J Hepatol.2006; 44:69-70.
9 Akpolat N, Yahsi S, Godekmerdan A, et al. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol.2005;11:3260-3.
11 Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA.1990; 87(17):6599-603.
11 Chen M, Sallberg M, Hughes J, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol.2005;79(5):3016-27.
12 Chen MT, Billaud JN, Sallberg M, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA.2004;101(41):14913-8.
13 Reignat S, Webster GJ, Brown D, et al. Escaping high viral load exhaustion:CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med.2002;195(9):1089-101.
14 Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8t T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B:implications for immunotherapy. J Virol. 2004;78(11):5707-19.
15 Vierling JM. The immunology of hepatitis B. Clin Liver Dis.2007;11:727-59, vii-viii.
16 Ferrari C, Missale G, Boni C, et al. Immunopathogenesis of hepatitis B. J Hepatol.2003;39 Suppl 1:S36-42.
17 Kondo Y, Kobayashi K, Ueno Y, et al. Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J Gastroenterol.2006; 12:4310-7.
18覃小敏,宁琴.重型肝炎发病的分子机制研究进展.国外医学.流行病学传染病学分册.2004；31(3)：150-154.
19 Imamum T,Yokosuka O,Kurihara T,et al.Distribution of hepatitisB viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan.Gut.2003;52(11):1630-1637.
20 Hou JL, Lin Y, Waters J, et al. Detection and significance of a G1862T Variant of hepatitis B virus in Chinese patients with fulminant hepatitis.J Gen Virol. 2002;83:2291-2298.
21 Ando K, Moriyanra T, Guidoti LG, et al. Mechanisms of class I restricted imnamopathology.A trensgenic mouse model of fulminant hepatitis.J Exp Med.1993;178(5):1541-1554.
22 Liblau RS, Singer SM, McDevitt HO.Thl and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases[J]. Immunol Today.1995; 16: 34-8.
23 Romagnani S. Th1 and Th2 in human diseases[J]. Clin Immunol Immunopathol. 1996; 80:225-35.
24赵爽,颜学兵,王金章,郝俊贵,汪明珊,冯霞,万美容.慢性乙型肝炎外周血细胞毒性T细胞亚群(Tc1／Tc2)失衡的研究.临床肝胆病杂志,2008；24：417-19.
25欧国生.类风湿性关节炎患者Th1／Th2、Tc1／Tc2细胞的检测及意义.实用医技杂志,2006；13：849-51.
26 Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity[J]. Nat Immunol.2007;8:345-50
27 Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature.2006 May 11;441(7090):235-8.
28 Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells. Cell.2006 Sep 22;126(6):1121-33.
29 Semple JW, Milev Y, Cosgrave D,Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura:relationship to platelet phenotype and antiplatelet T-cell reactivity[J]. Blood.1996;87:4245-54.
30 Ogawara H, Handa H, Morita K, Hayakawa M, Kojima J, Amagai H, et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura[J]. Eur J Haematol.2003;71:283-8.
31 Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response[J].Blood.2004; 103:2645-7.
1 Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med, 1996,183:2593-603.
2 Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev,2003,14:155-74.
3 Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity, 2004,21:467-76.
4 Aggarwal S, Gurney AL. IL-17:prototype member of an emerging cytokine family. J Leukoc Biol,2002,71:1-8.
5 Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J,2001,20:5332-41.
6 Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol, 2001,108:430-8.
7 Awane M, Andres PG, Li DJ, et al. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol,1999,162:5337-44.
8 Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity,1995,3:811-21.
9孙创斌胡晋红朱全刚刘继勇刘艳霞.药物作用新靶点：白细胞介素17及其受体.国际药学研究杂志,2008,3：169-172.
10 Miossec P. Interleukin-17 in rheumatoid arthritis:if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum,2003,48:594-601.
11张景熙.IL-17的研究进展.国外医学免疫学分册,2003,6：315-318.
12 Sylvester J, Liacini A, Li WQ, et al. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3,-13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal,2004,16:469-76.
13 Kim KW, Cho ML, Park MK, et al. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther,2005,7:R1 39-48.
14 Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis:lessons from animal models. Arthritis Res Ther, 2005,7:29-37.
15 Nielsen OH, Kirman I, Rudiger N, et al. Upregulation of interleukin-12 and-17 in active inflammatory bowel disease. Scand J Gastroenterol,2003,38:180-5.
16 Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut,2003,52:65-70.
17唐碧霞,张炬,唐福林.IL-17与自身免疫性疾病关系的研究进展.基础医学与临床,2008,28：94-97.
18 Yasumi Y, Takikawa Y, Endo R, et al. Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol Res,2007,37:248-54.
19 Loong CC, Hsieh HG, Lui WY, et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol, 2002,197:322-32.